ECOR1 CAPITAL LLC
Q2 2024 Form 13-F
SAN FRANCISCO, CALIFORNIA
CIK 0001587114
· CRD 167121
· SEC-registered investment adviser
$3.3B Reported Value Total
ECOR1 CAPITAL, LLC reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $5,001,741,440, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
5 funds
· $3.4B gross asset value
Hedge Fund: $3.4B · Venture Capital Fund: $65.4M
Source: Form ADV filed 2026-03-30
Reported value
$3.3B
Quarter over quarter
-17.5%
Holdings
55
Top-10 concentration
61.4%
Filing Structure
Reports holdings for
- NODELMAN OLEG (not a 13F filer in our records) · File #028-16767 · Q4 2014 – Q4 2014
Key People
Form ADV owners & control persons
Sarah Christine Marriott
MEMBER, CCO, COO
Oleg Nmn Nodelman
MANAGER
Scott Eric Perlen
CFO
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $3.3B |
| Positions | 55 |
| Change in reported value | -17.3% |
| New positions | 7 |
| Exited positions | 9 |
| Position turnover | 25.0% |
| Top-10 concentration | 61.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
31 | $2.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
29 | $2.4B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
28 | $2.2B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
30 | $2.1B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
36 | $1.7B |
|
Q1 2025 13F
Filed May 15, 2025
|
44 | $1.7B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
55 | $2.6B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
63 | $2.9B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
55 | $3.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
57 | $4.0B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
51 | $3.9B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
49 | $3.0B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
51 | $4.1B |
|
Q1 2023 13F
Filed May 15, 2023
|
58 | $3.1B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
66 | $3.3B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
75 | $3.4B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
78 | $2.9B |
|
Q1 2022 13F
Filed May 16, 2022
|
86 | $3.2B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
75 | $3.1B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
69 | $2.9B |
27 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | APLS APELLIS PHARMACEUTICALS INC | $445.3M | 13.62% |
| 2 | PRTA PROTHENA CORP PLC | $239.1M | 7.31% |
| 3 | SRPT SAREPTA THERAPEUTICS INC | $222.4M | 6.8% |
| 4 | ANAB ANAPTYSBIO INC | $188.5M | 5.77% |
| 5 | CRNX CRINETICS PHARMACEUTICALS IN | $186.1M | 5.69% |
| 6 | ARVN ARVINAS INC | $179.1M | 5.48% |
| 7 | MORF MORPHIC HLDG INC | $169.8M | 5.19% |
| 8 | LKFT GALAPAGOS NV | $142.6M | 4.36% |
| 9 | KURA KURA ONCOLOGY INC | $119.6M | 3.66% |
| 10 | TNGX TANGO THERAPEUTICS INC | $114.4M | 3.5% |
| 11 | ZYME ZYMEWORKS INC | $114.4M | 3.5% |
| 12 | JAZZ JAZZ PHARMACEUTICALS PLC | $108.2M | 3.31% |
| 13 | XNCR XENCOR INC | $100.9M | 3.09% |
| 14 | CRSP CRISPR THERAPEUTICS AG | $75.0M | 2.3% |
| 15 | JANX JANUX THERAPEUTICS INC | $61.6M | 1.88% |
| 16 | NUVB NUVATION BIO INC | $56.1M | 1.72% |
| 17 | CNTA CENTESSA PHARMACEUTICALS PLC | $51.6M | 1.58% |
| 18 | ITOS ITEOS THERAPEUTICS INC | $48.2M | 1.48% |
| 19 | IMNM IMMUNOME INC | $46.9M | 1.44% |
| 20 | NGNE NEUROGENE INC | $46.3M | 1.42% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.